Table 1.
Characteristics of LGA Embolization Studies
| First Author, Year (Reference) |
Design | No. Patients |
Indication | Follow-up (range), mo |
Institution, Country |
|---|---|---|---|---|---|
| Obesity clinical trials | |||||
| Weiss, 2019 (21) | Prospective | 15 | Severe obesity (BMI 40–60) | 15 (NA) | The Johns Hopkins Hospital, USA |
| Elens, 2019 (20) | Prospective | 11 | Overweight (BMI 25–30) | 6 (NA) | Hospital Erasme, Belgium |
| Pirlet, 2019 (23) | Prospective | 7 | Obesity (BMI > 40) | 12 (NA) | Bács-Kiskun County Hospital, Hungary |
| Bai, 2018 (14) | Prospective | 5 | Obesity (BMI > 30) | 9 (NA) | Southeast University, China |
| Syed, 2016 (17) | Prospective | 4 | Morbid obesity (BMI > 40) | 6 (NA) | Wright State University, USA |
| Kipshidze, 2015 (16) | Prospective | 5 | Obesity† | NA (20-24) | New York Cardiovascular Research, USA |
| GI bleeding studies | |||||
| Takahashi, 2019 (22) | Retrospective | 16 | GI bleeding | 1.5 | Mayo Clinic, USA |
| Kim, 2018 (15) | Retrospective* | 21 | GI bleeding | 12 (2–72) | Mallinckrodt Institute of Radiology, USA |
| Gunn, 2014 (9) | Retrospective | 19 | GI bleeding | 13.6 (NA) | Massachusetts General Hospital, USA |
BMI = body mass index; GI = gastrointestinal; LGA = left gastric artery; NA = not available.
*
Embolization of additional vessels was performed per individual study protocols.
†
BMI criteria was not specified, although mean (± SD) BMI was 42 ± 6.8.